About us
LASCCO has developed PSP, a new diagnostic test that warns high-risk of developing sepsis.
PSP commercial rights licensed to Abionic SA, which IVD CAPSULE PSP test has received 510(k) clearance from the US FDA and is certified under the EU IVDR.
In 2023, LASCCO and Abionic entered into a strategic partnership with Fapon to bring the PSP solution in China.
PSP commercial rights licensed to Abionic SA, which IVD CAPSULE PSP test has received 510(k) clearance from the US FDA and is certified under the EU IVDR.
In 2023, LASCCO and Abionic entered into a strategic partnership with Fapon to bring the PSP solution in China.
Accelerate time-to-recognition of sepsis
Pancreatic Stone Protein (PSP)
Unmatched sepsis biomarker
The PSP test complements clinical assessment to improve patient triage
PSP closely correlates with sepsis progression, allowing to timely activate sepsis bundles
Accurate in confounding settings such as burn injuries, post-trauma or post-surgery
Sepsis is a public health crisis
Sepsis arises when the body’s response to an infection injures its own tissues and organs. It may lead to shock, multi-organ failure, and death – especially if not recognized early and treated promptly. Sepsis is the most deadly and expensive condition treated in hospitals.
50 million
cases per year
> 11 million
deaths per year
No. 1
healthcare costs
PSP test - Results within minutes
Currently commercialized by LASCCO's strategic partner, Abionic SA.
Developed for China by Fapon.
Abionic's IVD CAPSULE PSP
- Delivers lab-quality results from a drop of blood.
- Cleared by the FDA - 510(k)
- Certified under the EU CE, EU IVDR, and TGA
Fapon's PSP CLIA solution
In collaboration with Abionic and LASCCO, Fapon is bringing the PSP solution on its chemiluminescent immunoassay (CLIA) analyzer in China
News
Team
Samareh Azeredo da Silveira
Managing Director
Frédéric Lajaunias
Managing Director
Toni Perez
Medical Director